H.E.L. Group Ltd, a global manufacturer of innovative laboratory tools for process optimization, safety and scale-up, announced the appointment of Louise Madden as Chief Executive Officer (CEO).
- Louise Madden joins as CEO to drive Company’s growth strategy
- Investment by Connection Capital supports H.E.L. Group in servicing global demand for its products, including fast-growth markets in Asia
Borehamwood, UK, 25 September 2019: H.E.L. Group Ltd, a global manufacturer of innovative laboratory tools for process optimization, safety and scale-up, today announced the appointment of Louise Madden as Chief Executive Officer (CEO). The announcement follows on from the Company having also secured a £5.9 million GBP (~$7.3 million USD) investment from UK-based private equity firm Connection Capital. The investment will be used to ensure the highest levels of product innovation, delivery and post-sales support for its global customers, in addition to accelerating sales in high growth markets such as the US, China and India.
Louise Madden, new CEO of the H.E.L. Group
Louise joins H.E.L. Group from Applied Photophysics where she was CEO, and also held positions as Chief Operating Officer and Commercial Director. Her experience within the analytical instruments field spans more than a decade, having been Global Service Manager at Biolin Scientific AB, and previously Finance Director at Farfield Group Limited. With a BA in Law and Accountancy from the University of Manchester, Louise spent 11 years at KPMG, where her clients ranged from owner-managed businesses to multi-national PLCs. During this time, Louise also gained extensive experience of mergers and acquisitions.
The scientific instruments and software designed, developed and manufactured by H.E.L. Group make it possible to optimize the efficiency and productivity of process scale-up across a wide range of chemistry and biology R&D applications. The Company has a long history of solving complex challenges for its customers working in fields spanning pharma, biotech, chemicals, energy and petrochemicals.
With the support of Connection Capital, the Company will continue to invest in the development of H.E.L. Group’s innovative technology and software platforms, and to bolster post-sales teams with additional resources in service and technical support. Significant investment in process and infrastructure improvements will also be carried out, with an increased focus on value-added activities not only for customers, but also as part of staff development.
In addition, H.E.L. Group plans to extend its reach into rapidly developing markets such as India and China, where the Company’s instruments, software and automated solutions are playing a pivotal role in improving the safety of chemical and industrial processes.
Louise Madden, CEO of H.E.L. Group, said: “H.E.L. Group has been working with customers for over 30 years to develop and better understand complex R&D processes that ultimately will help create a healthier, safer and more sustainable world. From an already strong and profitable base, we have ambitions to extend our reach in existing and new geographies. The investment by Connection Capital acts as a real catalyst for us to make the investment in our people, processes, infrastructure and product innovation to facilitate H.E.L.’s growth. I’m exciting to be steering the H.E.L. team, and look forward to us realizing our full market potential.”
For further information please contact:
Zyme Communications
Sarah Jeffery
Tel: +44 (0)7771 730919
E-mail: sarah.jeffery@
To opt-out from receiving press releases from Zyme Communications please e-mail info@zymecommunications.com. To view our privacy policy, please click here.
About H.E.L. Group www.helgroup.com
H.E.L. Group develops and manufactures innovative scientific instruments and software to optimize efficiency and productivity of process scale-up in chemistry and biology R&D applications.
With a team of 70, including highly skilled process and software engineers, and extensive research and manufacturing facilities in the UK, H.E.L. Group has a long history of solving complex challenges for customers. For more than 30 years the Company has worked with businesses and laboratories globally, providing proprietary automated solutions in the pharma, biotech, chemicals and petrochemicals sectors.
Following significant growth, and with annual revenues exceeding £10 million, the Company has plans to extend the reach of its products to support and enable R&D and process optimization further across the US, China and India.
